Gamma Vinyl Gamma Aminobutyric Acid (GVG), also known as Vigabatrin, is a medication primarily used for the treatment of epilepsy. It is considered an anticonvulsant drug that works by inhibiting the breakdown of gamma-aminobutyric acid (GABA) in the brain. GVG is classified as an irreversible inhibitor of the enzyme called GABA transaminase, which is responsible for breaking down GABA, an inhibitory neurotransmitter that helps regulate the excitation of nerve cells.
By preventing the breakdown of GABA in the brain, GVG increases the levels of this neurotransmitter, thus enhancing its inhibitory effects. This ultimately leads to a reduction in abnormal electrical activity and the occurrence of seizures.
GVG is typically prescribed for patients with complex partial seizures, a type of epilepsy that involves abnormal electrical activity in specific regions of the brain. It is also occasionally used as an adjunct therapy for other types of seizures, such as infantile spasms or generalized tonic-clonic seizures.
Although GVG has shown efficacy in controlling seizures, it is important to note that it may cause certain side effects, including dizziness, fatigue, weight gain, and visual disturbances. Some studies have also suggested a potential risk of vision loss, particularly peripheral visual field defects, with long-term use. Therefore, regular monitoring of visual function is advised for individuals receiving GVG treatment.
In conclusion, Gamma Vinyl Gamma Aminobutyric Acid (GVG) is an anticonvulsant medication used to control seizures by increasing the levels of the inhibitory neurotransmitter GABA in the brain.
